Biocon has acquired an Establishment Inspection Report (EIR) from the USFDA for its Biologics Drug Product facility in Bengaluru, stating the inspection is closed.
Biocon had undergone a surveillance (routine) cGMP inspection of this Drug Product facility in Bengaluru from 22 August to 30 August 2019.
The receipt of EIR shows a a success closure of this inspection.
Bazaarinformation team has many years of experience, covering the physical and future commodities markets with prominent commodity & equity trading advising which shines further with extensive network to get research from ground levels to generate proper reporting and movements. We are able to get evens out of odds in volatile markets and stockings. ...
